Caliper Life Sciences, Inc. (Nasdaq: CALP) today announced preliminary revenue results for its 2008 fourth quarter and full year ended December 31, 2008.

Based on the company’s preliminary financial results, total revenue is expected to be approximately $36.5 million for the fourth quarter of 2008 and approximately $133.9 million for the full year, which is at the upper end of the company’s previous revenue guidance for the fourth quarter of $34 million to $37 million.

Earlier in the fourth quarter, Caliper announced the sale of its Pharmaceutical Development & Quality and AutoTrace product lines in transactions valued in the aggregate at approximately $21.0 million. 2008 pro forma revenue, reflecting the divestiture of these two product lines, for the fourth quarter and full year is expected to be approximately $34.6 million and $122.8 million, respectively.

Fourth quarter and full year preliminary revenue results are pending finalization of the company’s financial results for the quarter and year ended December 31, 2008 and accordingly are subject to change.

2009 Revenue Guidance

For 2009, Caliper currently expects total revenue to increase by approximately 4% to 7% compared with 2008 pro forma revenue, with the growth primarily occurring in the second half of the year. The company cited currency headwinds as a key factor influencing its estimates.

Presentation at Today’s J.P. Morgan Conference

As announced in a separate press release issued by the company on December 23, 2008, Caliper will today make a presentation at the J.P. Morgan Healthcare Conference in San Francisco, California. A live webcast of the company’s presentation can be accessed at http://metameetings.com/webcasts/jpmorgan/healthcare09/directlink?ticker=CALP. An archived edition of the presentation will be available for 90 days.